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SUMMARY
Over the past decade, amniotic fluid-derived stem cells have emerged as a novel experimental approach aimed at improving out-
comes in children with congenital anomalies, including spina bifida, heart defects, and diaphragmatic hernia. Interest in these cells
for the treatment of prenatally diagnosed diseases has arisen based on numerous studies demonstrating the relative ease of har-
vesting an abundant quantity of amniocytes from a small aliquot of fluid, the unique properties of amniocytes themselves, and
the beneficial effects of amniotic fluid-derived stem cells in experimental animal models. This report gives a brief overview of the
rationale and current status of amniotic fluid stem cell-based therapies, focusing on its relevance to birth defects affecting the
fetus and neonate. The author proposes a roadmap for further study that would be required prior to clinical application of amni-
otic fluid stem cell technologies. STEM CELLS TRANSLATIONAL MEDICINE 2018;7:767–773
SIGNIFICANCE STATEMENT
This article gives a pediatric surgeon-scientist’s perspective on the therapeutic potential of amniotic fluid-derived stem cells in
the management of a wide range of structural birth defects affecting the fetus and neonate. The characteristics of amniotic
fluid-derived stem cells are discussed in experimental animal models of congenital anomalies, including spina bifida, congenital
heart disease, and congenital diaphragmatic hernia. Barriers to the clinical translation of amniotic fluid stem cells as a potential
adjunct to surgical treatment in children are reviewed.
INTRODUCTION
Structural birth defects are the end products of aberrant organo-
genesis early in fetal life. Some of the more common prenatally
diagnosed anomalies encountered by surgeons in the neonatal
intensive care unit include congenital diaphragmatic hernia
(CDH), abdominal wall defects, spinal bifida, and congenital heart
disease. Thanks in part to the enhanced resolution of fetal ultra-
sound imaging, the vast majority of these anomalies are diag-
nosed during the second trimester of pregnancy, thereby
allowing families the time to seek advanced perinatal care at a
major pediatric referral center. However, despite advances in the
medical and surgical care of these patients, these anomalies
continue to inflict a major burden of pediatric disease and
account for a significant proportion of infant mortality, morbid-
ity, andhospitalization days worldwide. In the effort to further
improve clinical outcomes in these young children, there has
been increasing interest in the clinical application of various pro-
genitor cell populations derived from amniotic fluid as a novel
therapeutic adjunct to organ regeneration and surgical recon-
struction in various pediatric disease processes [1–5].
RATIONALE FOR AMNIOTIC FLUID-DERIVED STEM CELLS
The use of amniotic fluid stem cells represents a practical and
logical choice for autologous cell-based therapy in children with
prenatally diagnosed congenital anomalies for a number of rea-
sons. First, there is no need to wait until delivery for cell harvest-
ing since amniocytes are easily accessible by needle aspiration
(amniocentesis) of a small sample of amniotic fluid (e.g., 5 ml)
[6]. Because sampling amniotic fluid cells is already medically
indicated as part of the diagnostic evaluation for many fetal
anomalies to rule out aneuploidy, there is no added morbidity by
procuring additional fluid for potential therapeutic benefit. After
15 weeks gestation, an amniocentesis is a safe procedure with a
less than 1% rate of fetal loss when performed by experienced
personnel under ultrasound guidance [7]. By contrast, harvesting
stem cells prenatally from placenta, chorionic villi, cord blood,
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liver, or skin is more technically challenging and associated with a
higher risk of spontaneous abortion, infection, hemorrhage, and
other morbidities [8]. In fact, the safety of an amniocentesis has
now enabled commercial banking of amniotic fluid in some
developed countries.
Amniotic fluid-derived stem cells genetically originate from
the fetus itself, thereby allowing for autologous therapeutic
applications to be performed without concern for immunologic
rejection of donor cells upon delivery, either prenatally or in
the early postnatal period [9, 10]. Studies have shown that
second-trimester amniotic fluid stem cells can proliferate rap-
idly in culture compared to postnatal somatic cells under Good
Manufacturing Practice conditions [6]. Therefore, once the
prenatal diagnosis of the anomaly is made during the second
trimester, amniotic fluid stem cells can be easily expanded
in vitro and ready for use as an autologous therapy in the peri-
natal period [11, 12]. Given the relatively small size of the
fetus, the importance of this issue should not be underesti-
mated since a large number of cells may be required for thera-
peutic effect. In short, the use of amniotic fluid cell-based
approaches has substantial and clinically relevant advantages
over other fetal and postnatal cell sources, including bone
marrow and liver [13].
For many years, amniotic fluid was thought to be com-
posed primarily of fetal urine with terminally differentiated
epithelioid cells derived from the fetal skin and amnion. It
is now well recognized that preterm amniotic fluid contains
a heterogenous group of distinct progenitor cell popula-
tions, including CD34+ hematopoietic progenitors, c-kit−
mesenchymal stem/stromal cells (MSCs), and c-kit+ multipo-
tent stem cells [1]. Each of these amniotic fluid cell types
possesses its own unique tissue-specific characteristics that
lends itself to potential clinical translation based on differ-
entiation capacity, anti-inflammatory effects, and other tro-
phic properties that are known to promote tissue repair
and regeneration.
Amniotic Fluid-Derived Mesenchymal Stem Cells
Amniotic fluid-derived MSCs are a plastic-adherent population of
c-kit− cells that fulfill the minimal criteria for MSCs (e.g., CD34−,
CD45−, CD73+, CD90+, and CD105+) as originally described for
cells derived from bone marrow [14]. By definition, these cells
have restricted differentiation potential and have been shown to
differentiate into the osteogenic, adipogenic, and chondrogenic
lineages in vitro [15–18]. However, increased plasticity of amni-
otic fluid-derived MSCs (e.g., neural-like cells) has also been dem-
onstrated by some investigators, and others have found the
expression of many of the same core pluripotency genes as
undifferentiated embryonic cells, including OCT4 and SSEA4,
albeit at lower levels in most cases [34]. Pluripotent gene expres-
sion is usually variable due to their polyclonal nature and tends
to decrease with gestational age and time in culture [19]. Other
investigators have similarly shown that unselected amniocytes
have wide heterogeneity and express a range of genes and pro-
teins specific to pluripotent, committed progenitors as well as
fully differentiated cells [20, 21].
MSCs are perhaps best known for their potential immuno-
modulatory role in inflammatory conditions and disease pro-
cesses [22]. Although the mechanistic role of amniotic fluid-
derived MSCs in vivo remains poorly described, MSCs from
amniotic fluid have been shown to inhibit T-cell proliferation,
to decrease memory T cells, to increase T regulator lympho-
cytes, and to polarize the Th2 subtype in association with
increased IL-10 and IL-4 levels in coculture studies when com-
pared to MSCs derived from bone marrow and placenta [23].
It has been hypothesized that amniotic fluid-derived MSCs
may play a critically important paracrine role in the immune
response at the maternal-fetal interface through expression of
the CD59 and HLA-G, among others [9, 10].
c-kit+ Amniotic Stem Cells
Shortly after MSCs derived from amniotic fluid were first
reported, a specific subset of amniotic fluid stem cells expres-
sing c-kit (CD117), a tyrosine-kinase receptor that specifically
binds to the ligand, stem cell factor, was described by De Coppi
et al. [24]. These unique cells, which can be isolated using
immunomagnetic beads during primary culture, constitute less
than 1% of the total somatic cell population in amniotic fluid. c-
kit+ amniotic fluid cells express the same panel of MSCs pheno-
typic markers as c-kit− MSCs derived from amniotic fluid but are
clonal and capable of undergoing more than 250 population
doublings, far exceeding the Hayflick limit as defined by the
telomere length of the starting cell population. These cells have
been associated with improved regeneration of damaged
smooth muscle in rat cryoinjured bladders, among other tissues
[25]. Compared to MSCs derived from bone marrow or amniotic
fluid, c-kit+ amniotic fluid cells have much greater multipotent
differentiation potential in vitro with clonal cell lines demon-
strating differentiation into lineages within each of the three
germ layers, including neurogenic (ectoderm), cardiogenic
(mesoderm), and hepatogenic (endoderm) cell types [24, 26].
Despite these findings, c-kit+ amniotic fluid cells have not been
fully embraced as having equivalent pluripotency to human
embryonic stem cells or induced pluripotent stem cells (iPSCs).
Nonetheless, a key potential advantage of c-kit+ amniotic fluid
cells is that they are not known to form teratomas when
injected into immunodeficient mice and do not require xeno-
genic feeder layers to support their long-term growth in culture.
Similar to the situation with amniotic fluid-derived MSCs, inves-
tigators have suggested that the immunoprivileged characteris-
tics of c-kit+ stem cells may enable their use in allogeneic cell
therapy applications, particularly if the donor cells are ulti-
mately delivered in the fetal environment [27, 28].
A major drawback of working with c-kit+ amniotic fluid cells
comes from their rarity. Unlike AF-MSCs, which are abundant and
easily obtained until term, c-kit+ amniotic fluid cells cannot be reli-
ably isolated from late second trimester and third trimester sam-
ples [29]. These later time points are typically more clinically
relevant since they correspond to the time at which most congen-
ital anomalies are diagnosed by prenatal ultrasound. In general, c-
kit+ amniotic fluid cells isolation methods are also more laborious,
time consuming, and costly. For these reasons, c-kit+ amniotic
fluid cells may be best suited as an “off-the-shelf” product amend-
able toward allogeneic cell transplantation applications.
Induced Pluripotent Stem Cells Derived from
Amniocytes
The use of prenatal somatic cells from iPSCs represents
another novel strategy to regenerate perinatal tissues that can
be implanted to replace those that are severely damaged or
missing. Over the past decade, substantial efforts have also been
undertaken by numerous laboratories to reprogram early
© 2018 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by
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gestation amniocytes into pluripotent stem cells, enabling their
use shortly at birth [30–33]. The embryonic origins, inherently
primitive nature of certain populations (i.e., positive for OCT4,
SSEA3, and SSEA4), and nascent epigenetic background of
amniocytes may make them particularly well suited for rapid
and highly efficient (e.g., 0.5%) genetic reprogramming for thera-
peutic use [31, 33]. Indeed, investigators have suggested that
the absence of age-related epigenetic modifiers associated with
alterations in DNA methylation and chromatin structure may
help to explain why fewer than four Yamanaka reprogramming
factors have been shown to be sufficient for successful repro-
gramming [32]. More recently, various transgene-free repro-
gramming methods, including exclusively chemical-based
techniques free from ectopic factors, have been reported [34,
35]. iPSCs derived from amniotic fluid have also been shown to
have immunoregulatory properties by impairng NK cell cytotoxic-
ity, a mechanism that plays a role in allograft rejection [36].
SELECTED CONGENITAL ANOMALIES AMENABLE TO AMNIOTIC
FLUID STEM CELL THERAPIES
Neural Tube Defects
In myelomeningocele (MMC), one of the most severe types of
neural tube defects, the natural sequelae in affected children
include hydrocephalus, bowel and bladder incontinence, and
distal lower motor dysfunction. Fetal surgical repair has now
become the standard of care at some children’s hospital in the
U.S. based on a randomized trial demonstrating reduced hydro-
cephalus and modest gains in ambulation [37]. Regenerative
medicine-based strategies, aimed at decreasing spinal cord glio-
sis within the defect during fetal repair, could represent a major
additional advance in the quality of life for these children.
Several investigators have studied the role of amniotic fluid
stem cell-based therapies in animal models of fetal MMC
(Fig. 1) [38–40], primarily as a means to provide tissue coverage
in utero to protect the spinal cord from ongoing mechanical
and chemical damage. For example, Fauza and colleagues have
explored the intra-amniotic delivery of high doses of amniotic
fluid-based stem cells (termed trans-amniotic stem cell therapy,
TRASCET). In this model, the cells have been shown to preferen-
tially home to the neural tube defect to provide partial cover-
age of the spinal cord in syngeneic fetal rat models of MMC
[39, 41]. Another group of investigators has demonstrated the
therapeutic concept of amniotic fluid-based tissue engineering
by repairing fetal rat neural tube defects using three-
dimensional tissue-engineered skin from amniocytes. In this
short-term pilot study, the epidermal layer was generated from
keratinocytes derived from human amniotic fluid iPSCs, whereas
the dermis was created from human fibroblasts and collagen
type I [40]. Although promising, the long-term effectiveness of
these stem cell-based strategies on functional spinal cord regen-
eration cannot be shown because postnatal survival is not feasi-
ble in any of the available rodent MMC models. Carefully
conducted large animal studies using fetal lambs will likely be
required in order to bring this technology to the clinical arena
[42]. Strategies such as the transplantation of amniotic fluid-
derived neural stem cells may offer additional benefits in terms
of facilitating bona fide regeneration of neural derivatives. If
amniotic fluid-based stem cell therapies do eventually show evi-
dence of enhanced neurologic function, one could easily envi-
sion a treatment paradigm in the future that would include
deriving autologous stem cells following an amniocentesis once
the diagnosis is made by ultrasound, typically between 16 and
20 weeks gestation. The amniotic fluid-derived cells would be
isolated and subsequently delivered to the MMC spinal cord
injury later in gestation or at postnatal spinal cord closure.
Congenital Heart Disease
Congenital heart defects are the most common major birth
defects seen in children’s hospitals worldwide, and those at
the most severe end of the spectrum are diagnosed during the
Figure 1. Tissue engineering from amniotic fluid-derived stem cells for the treatment of prenatally diagnosed congenital anomalies. (A):
Schematic diagram of autologous fetal stem cells obtained by amniocentesis during the second trimester, followed by ex vivo expansion
of amniocytes in parallel with the remainder of gestation, and subsequent seeding of cells within biodegradable scaffolds in preparation
for perinatal surgical implantation. Gross appearance of the lumbosacral neural tube defect in a fetal rat with myelomeningocele (MMC)
(B) without treatment and (C) with treatment with amniotic fluid-derived mesenchymal stem cells in utero. (D): Hematoxylin and eosin
photomicrograph of a representative rat MMC defect at term after treatment with amniotic fluid-derived mesenchymal stem cells in
utero, showing rudimentary skin coverage (within dotted ellipse). Modified from [7, 31] with permission.
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second trimester by fetal echocardiography. An alternative,
regenerative medicine-based approach to conventional thera-
pies, including cardiac transplantation, would be to generate
autologous replacement cardiomyomyocytes specific to each
patient. c-kit+ amniotic stem cells have been shown to differen-
tiate into cardiomyocytes [26, 43]. More recently, the differenti-
ation of cells from autologous amniotic fluid iPSCs into
functional cardiomyocytes by integration-free reprogramming
methods has also been demonstrated (Fig. 2) [44, 45]. Amniotic
fluid-derived stem cells are likely to play an additional role as
paracrine mediators of tissue regeneration based on experimen-
tal models of adult heart disease [28, 46]. Although research in
this area is quite preliminary, future work with the scale up and
preconditioning of cardiomyocytes derived from amniotic fluid
cells has enormous potential in helping to circumvent the scar-
city of heart donors for infants born with severe heart failure
because of hypoplastic left heart syndrome.
Surgical reconstruction of the heart valves and great ves-
sels in children is currently performed using a prefabricated
acellular prosthetic implant. Unfortunately, these implants typ-
ically fail to grow with the child into adulthood, resulting in
the need for multiple operations to optimize heart function.
By contrast, a cellularized, tissue-engineered prosthetic would
theoretically have the ability to grow and remodel over time,
thereby avoiding serial revisional operations. Such an implant
would also not mandate the need for long-term anticoagula-
tion. To date, the greatest experience with amniotic fluid
based-stem cell technologies has been with the fabrication of
tissue-engineered heart valves [47, 48]. In one such study,
Hoestrup and colleagues successfully created functional heart
valves derived from human amniotic fluid cells [47]. The cells
were seeded onto synthetic heart valve leaflet scaffolds and
conditioned within a pulse bioreactor to facilitate their matu-
ration. Microscopic analyses revealed endothelialized tissue
Figure 2. Generation of beating cardiomyocytes from pluripotent cells derived from human amniotic fluid. (A): Representative confocal
microscopy images of cardiomyocyte subtypes exhibiting comparable mixed immunostaining patterns of sarcromeric proteins, including ven-
tricle (MLC2v, FITC secondary, green) and other cardiac-specific markers, including MYH7, MF20, MLC2a, and TTNT2 (magnification, ×40).
(B): Representative pseudocolor activation map of intracellular calcium transient propagation in amniotic fluid cardiomyocyte monolayers
showing typical radial spreading patterns after spontaneous activation. Isochrone lines (right) indicate differential activation times. (C): Rep-
resentative calcium transient recordings after β-adrenergic agonist (50 nM ISO) exposure of amniotic fluid cardiomyocytes demonstrating
appropriate chronotropic responses compared to baseline. Modified from [35] with permission. Abbreviation: ISO, isoproterenol.
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formation as well as biomechanical properties sufficient for
implantation in vivo. Subsequent work in large animal models
has demonstrated short-term in vivo functionality with intact
valvular integrity and absence of thrombus formation [48].
Respiratory Tract Anomalies
In CDH, the fetal diaphragm fails to correctly form, resulting in
herniation of the abdominal viscera into the chest cavity. The
diagnosis is made in the vast majority of cases by ultrasound
at 18–20 weeks gestation. Although large holes in the dia-
phragm can be closed with a synthetic patch in the newborn
period, recurrent herniation as the child grows is a well-known
complication following repair. Similar to the problems associ-
ated with prosthetic heart valves, it has been argued that a
fully cellularized implant that has the ability to grow and
remodel over time represents the ideal prosthesis for the CDH
patient population. Fauza and colleagues have extensively
explored this concept using sheep amniotic fluid-derived fibro-
blasts resuspended in collagen hydrogels and seeded onto
decellularized dermal scaffolds (Supporting Inforamtion
Fig. S1) [49, 50]. In these studies, the amniocytes were used to
reconstruct a diaphragmatic defect in neonatal lambs, demon-
strating lower rates of reherniation as well as improved modu-
lar and ultimate tensile strengths over time. Clinical trials
using this treatment strategy are forthcoming.
In recent years, amniotic fluid stem cell-based induction of
lung growth has become another area of interest for the treat-
ment of lung hypoplasia associated with CDH, giant omphalo-
cele, and bronchopulmonary dysplasia. Given the known
association of oligohydramnios with lung hypoplasia, it has been
theorized that amniotic fluid-derived stem cells may secrete
growth factors that promote fetal growth vis-à-vis paracrine
mediators and/or exosomes [51]. Evidence for enhanced lung
regeneration with amniotic fluid-derived stem cells in experi-
mental CDH models has been shown by numerous investigators
[52–54]. In an ex vivo fetal lung study [53], amniotic fluid MSCs
augmented branching morphogenesis and lung epithelial matu-
ration in the nitrofen rat model of CDH lung hypoplasia. Since
nearly 30% of CDH neonates die secondary to overwhelming
pulmonary hypoplasia and pulmonary hypertension, fetal aug-
mentation of lung growth with amniotic fluid stem cell delivery
might have a major clinical impact in severely affected fetuses.
Severe obstructive malformations of the trachea, including
tracheal agenesis and atresia, are rare but well-described entities
in pediatric surgery. Methods of definitive tracheal reconstruc-
tion are currently limited by a paucity of available autologous tis-
sue that can mimic the structural and mechanical properties of
native airway cartilage. Chondrocytes derived from amniotic
fluid-derived MSCs could serve as a viable alternative for early
tracheal repair soon after birth (Supporting Inforamtion Fig. S2).
This therapeutic concept has been successfully demonstrated in
an ovine model of tracheal repair [55]. In this study, GFP-labeled
sheep amniocytes were seeded onto cylindrical polyglycolic acid-
based scaffolds and exposed to a chondrogenic medium contain-
ing transforming growth factor beta. The constructs were then
used to reconstruct partial- or full-circumferential tracheal
defects in fetal lambs. Neonatal lambs were able to breathe at
birth without major respiratory distress, and there was evidence
of donor cell survival as revealed by GFP+ cells within fibrous
cartilage. Of note, the successful implantation of a tissue-
engineered airway structure derived from autologous bone
marrow MSCs has already reported in a child [56]. However, to
help bring this technology toward widespread clinical applica-
tion, more research is clearly needed to evaluate the effect of
novel biodegradable scaffolds with biomechanical properties that
would enable long-term tracheal growth and function.
Perinatal Gastrointestinal Disorders
Because of the known immunomodulatory properties of amni-
otic fluid stem cell populations with regards to decreasing T-cell
proliferation and polarizing the Th2 subtype in association with
increased IL-10 and IL-4 levels, inflammatory disorders of the
gastrointestinal tract in fetuses and neonates may be amenable
to amniotic fluid cell-based approaches. One such condition is
gastroschisis, a congenital birth defect characterized by a failure
of the abdominal wall to properly form at 10 weeks gestation.
This subsequently leads to herniation of the abdominal viscera
into the abdominal cavity with progressive chemical and
mechanical damage to the small intestines while in utero. Simi-
lar to the case with MMC, TRASCET may have salutary, anti-
inflammatory effects on fetal gastroschisis intestines once the
diagnosis is made in the fetus by ultrasound at 16–20 weeks
gestation. TRASCET has been shown to improve intestinal histol-
ogy at birth in a fetal rodent model of gastroschisis [57].
Although not considered to be a congenital anomaly per
se, several investigators have also published promising data on
amniotic fluid-derived stem cells to abrogate the inflammatory
response in necrotizing enterocolitis. Necrotizing enterocolitis
is a potentially lethal disease (i.e., 40% mortality) that affects
mostly premature infants and leads to progressive intestinal
damage and necrosis [58, 59]. Surgical removal of severely
damaged intestines can be life saving, but current medical
therapies, including antibiotics, are merely supportive and do
little to halt the progressive inflammatory process in this dis-
ease. In the future, c-kit+ donor cells or autologous amniotic
fluid could be harvested in a sterile fashion at delivery for
therapeutic purposes as described by others [18]. One poten-
tial mechanism for the effectiveness of amniotic fluid stem
cells may be by a reduction in intestinal permeability in neona-
tal rodent models [58].
SUMMARY AND FUTURE DIRECTIONS
The field of amniotic fluid stem cell therapy in the manage-
ment of perinatal disease has enormous potential. Thus, it is
not surprising that it has developed into one of the most fur-
tile areas of translational research among fetal/pediatric scien-
tists within the regenerative medicine community. Given the
obvious clinical feasibility of amniotic fluid stem cell-based
therapies in those with prenatally diagnosed congenital anom-
alies, it is likely only a matter of time until some of the suc-
cessful results that have already been demonstrated in
preclinical animal models can be safely translated in humans.
Nevertheless, several limitations in this emerging field
deserve special mention. First, as with most stem cell-based
therapies, we need to better define the optimal phenotype
within a heterogeneous group of cells for each clinical applica-
tion. Second, the biological basis for the paracrine function
(e.g., growth factors, exosomes, etc.) of amniotic fluid stem
cells remains to be elucidated. Third, determining the optimal
gestational age for amniotic fluid stem cell isolation as well as
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dose/timing of therapy has made optimization for clinical use
quite challenging. Fourth, the preparation of amniotic fluid
stem cell for therapy may be variable and subject to large
donor-specific factors that have yet to be determined [60].
Fifth, amniotic fluid cell-based cultures often require the use
of xenogeneic reagents that are either currently discouraged
for human use or require close regulation by clinical safety
boards, such as the Food and Drug Administration in the
U.S. Finally, progress in amniotic fluid stem cell-based therapy
remains hampered by the relative rarity of each of these con-
genital anomalies, which often prohibits the ability to ade-
quately study the efficacy of these novel treatments in a single
center controlled trial. Overcoming these challenges will be
essential if pediatric physicians and scientists are to bring
these innovative and promising treatments to clinical fruition
for the smallest and most vulnerable members of our society.
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